Abstract:Based on a multitarget strategy, a series of novel tacrine–pyrimidone hybrids were identified for the potential treatment of Alzheimer's disease (AD). Biological evaluation results demonstrated that these hybrids exhibited significant inhibitory activities toward acetylcholinesterase (AChE) and glycogen synthase kinase 3 (GSK-3). The optimal compound 27g possessed excellent dual AChE/GSK-3 inhibition both in terms of potency and equilibrium (AChE: IC50 = 51.1 nM; GSK-3β: IC50 = 89.3 nM) and displayed significant amelioration on cognitive deficits in scopolamine-induced amnesia mice and efficient reduction against phosphorylation of tau protein on Ser-199 and Ser-396 sites in glyceraldehyde (GA)-stimulated differentiated SH-SY5Y cells. Furthermore, compound 27g exhibited eligible pharmacokinetic properties, good kinase selectivity, and moderate neuroprotection against GA-induced reduction in cell viability and neurite damage in SH-SY5Y-derived neurons. The multifunctional profiles of compound 27g suggest that it deserves further investigation as a promising lead for the prospective treatment of AD.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00160?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00160</a>.Experimental methods for biological assays and figures, tables, NMR spectra, HPLC spectra, and MS spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00160/suppl_file/jm1c00160_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00160/suppl_file/jm1c00160_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer's disease.

Tacrine–propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease

Tacrine-hydroxamate Derivatives As Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Design, Synthesis, and Biological Evaluation.

Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.

Design, Synthesis and Biological Evaluation of Tacrine-1,2,3-triazole Derivatives As Potent Cholinesterase Inhibitors.

Synthesis and Evaluation of Heterobivalent Tacrine Derivatives As Potential Multi-Functional Anti-Alzheimer Agents

Synthesis and bioevaluation of new tacrine-cinnamic acid hybrids as cholinesterase inhibitors against Alzheimer's disease.

Discovery of Novel Tacrine–Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer’s Disease

A Novel Series of Tacrine-Selegiline Hybrids with Cholinesterase and Monoamine Oxidase Inhibition Activities for the Treatment of Alzheimer'S Disease

Searching for the Multi-Target-Directed Ligands Against Alzheimer’s Disease: Discovery of Quinoxaline-Based Hybrid Compounds with AChE, H3R and BACE 1 Inhibitory Activities

Late-Stage Modification of Medicine: Pd-Catalyzed Direct Synthesis and Biological Evaluation of N -Aryltacrine Derivatives

East meets West in the search for Alzheimer's therapeutics - novel dimeric inhibitors from tacrine and huperzine A.

Tacrine-Flurbiprofen Hybrids As Multifunctional Drug Candidates for the Treatment of Alzheimer's Disease

Synthesis and Pharmacological Evaluation of Multifunctional Tacrine Derivatives Against Several Disease Pathways of AD

Synthesis and Activity Towards Alzheimer's Disease in Vitro: Tacrine, Phenolic Acid and Ligustrazine Hybrids.

Tacrine-flurbiprofen hybrids as multifunctional drug candidates for the treatment of Alzheimer's disease.

Design, synthesis, in vitro and in vivo evaluation of tacrine–cinnamic acid hybrids as multi-target acetyl- and butyrylcholinesterase inhibitors against Alzheimer's disease

Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease

Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential anti-Alzheimer's Disease Agents.

Design, synthesis and pharmacological evaluation of novel tacrine-caffeic acid hybrids as multi-targeted compounds against Alzheimer's disease.

Design, Synthesis and Evaluation of Novel Tacrine-Multialkoxybenzene Hybrids As Dual Inhibitors for Cholinesterases and Amyloid Beta Aggregation